Vaccines Market

The report "Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) - Global Forecast to 2028"global vaccines market (including covid-19 vaccines) is projected to reach USD 85.2 billion by 2028 from USD 74.8 billion in 2023, at a CAGR of 2.6% during the forecast period of 2023 to 2028. Similarly the global vaccines (excluding covid-19 vaccines) market is projected to reach USD 69.4 billion by 2028 from USD 45.3 billion in 2023, at a CAGR of 8.9% during the forecast period of 2023 to 2028

Browse 321 market data Tables and 57 Figures spread through 402 Pages and in-depth TOC on "Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) - Global Forecast to 2028"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html

The global vaccines market (including covid-19 vaccines) is expected to grow at a CAGR of 2.6% during the forecast period. Similarly the global vaccines market (excluding covid-19 vaccines) is expected to grow at a CAGR of 8.9% during the forecast period The growth of the market is projected to be driven by factors such as leveraging the increasing prevalence of infectious diseases, expanding immunization initiatives, robust government support & investment for vaccines development,  launch of novel vaccines and harnessing advancements in vaccine technology.

The mRNA vaccines segment is expected to have the dominant share of the vaccines market (including covid-19 vaccines) in 2023.

Based on technology, the global vaccines market (including covid-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines mRNA vaccines, inactivated & subunit vaccines, viral vector vaccines and others (subunit vaccines, peptide vaccines, DNA vaccines) . In 2023, the m-RNA vaccines segment held the largest share of the vaccines market. For instance, as of 2024, there are around 30 mRNA vaccines that are under phase 3 clinical trials with expected primary competition years of 2023-2026. Similarly in December 2023, Moderna, Inc. (US) announced a positive Phase 3 clinical study results for mRNA-1345 investigational RSV vaccine. The amplified government support coupled with heightened corporate investment in the realm of mRNA vaccine development are the driving factor for the growth of the mRNA vaccines segment during the forecast period.

The pneumococcal segment (excluding covid-19 vaccines) expected to account for the largest share of the disease indication segment in the  vaccines market in 2023.

Based on disease indication, the vaccines market (excluding covid-19 vaccines) is segmented into, influenza, combination vaccines, pneumococcal disease, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio and other disease indications (dengue, tuberculosis, typhoid, japanese encephalitis, rabies, yellow fever, allergies, and cancer). The pneumococcal disease segment is anticipated to grow at significant CAGR during the forecast period owing to various factors such as surge in pneumococcal disease prevalence, paralleled by a substantial rise in government investment in pneumococcal vaccination programs. For instance, in September 2022, Biological E Limited received approval from the Drugs Controller General of India (DCGI) for a 14-valent pediatric Pneumococcal Conjugate Vaccine (Investigational Pneumococcal Polysaccharide Conjugate Vaccine PCV14.

The Asia Pacific region (including & excluding covid-19 vaccines) is the fastest-growing region of the vaccines market in 2023.

The Asia Pacific (including & excluding covid-19 vaccines) is accounted to be the fastest-growing segment of the market. The growth of the vaccines markets in the region is driven by escalating corporate investments within the Asia-Pacific region, driven by a rising tide of government backing for vaccine development, emergence and re-emergence of communicable diseases, rising disposable income and establishing specialized department for vaccines research and development. For instance in 2023, Japan has set up a new vaccine research funding unit for future pandemics to make a safe and effective vaccine available within 100 days of an outbreak

The vaccines market is consolidated, with a small number of players competing for market shares.  GSK plc (UK), Merck & Co., Inc (US) Pfizer Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services, Inc (US), Astrazeneca (UK), Serum Institute Of India Pvt. Ltd (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company Limited (Japan), Panacea Biotec (India), Biological E Limited (India), Bharat Biotech (India) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Don’t miss out on business opportunities in Vaccines Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]